{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Nuzzo F"],"pubmed_abstract":["<h4>Background</h4>To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer.<h4>Methods</h4>Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2, chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients per arm were needed.<h4>Results</h4>From February 2004"],"journal":["BMC cancer"],"pagination":["75"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3050853"],"repository":["biostudies-literature"],"pubmed_title":["Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial."],"pmcid":["PMC3050853"],"pubmed_authors":["Perrone F","Rinaldo M","Rossi E","De Maio E","de Matteis A","D'Aiuto G","Gravina A","Morabito A","Di Bonito M","Di Rella F","Piccirillo MC","Nuzzo F","Pacilio C","Labonia V","Thomas R","Landi G","Botti G","Gallo C","Di Maio M"],"additional_accession":[]},"is_claimable":false,"name":"Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.","description":"<h4>Background</h4>To evaluate whether weekly schedules of docetaxel-based chemotherapy were superior to 3-weekly ones in terms of quality of life in locally advanced or metastatic breast cancer.<h4>Methods</h4>Patients with locally advanced or metastatic breast cancer, aged ≤ 70 years, performance status 0-2, chemotherapy-naive for metastatic disease, were eligible. They were randomized to weekly or 3-weekly combination of docetaxel and epirubicin, if they were not treated with adjuvant anthracyclines, or docetaxel and capecitabine, if treated with adjuvant anthracyclines. Primary end-point was global quality of life change at 6-weeks, measured by EORTC QLQ-C30. With two-sided alpha 0.05 and 80% power for 35% effect size, 130 patients per arm were needed.<h4>Results</h4>From February 2004","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Feb","modification":"2026-04-07T21:56:38.192Z","creation":"2026-04-07T18:19:48.34Z"},"accession":"S-EPMC3050853","cross_references":{"pubmed":["21324184"],"doi":["10.1186/1471-2407-11-75"]}}